Edition:
United Kingdom

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Global Market

8.19USD
24 Apr 2018
Change (% chg)

$0.07 (+0.86%)
Prev Close
$8.12
Open
$8.11
Day's High
$8.26
Day's Low
$7.95
Volume
3,202
Avg. Vol
4,671
52-wk High
$102.50
52-wk Low
$7.90

Latest Key Developments (Source: Significant Developments)

InVivo Therapeutics Announces Latest Results From INSPIRE
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS ANNOUNCES LATEST RESULTS FROM INSPIRE AND PROVIDES UPDATE ON PROPOSED CLINICAL PATH FORWARD.INVIVO THERAPEUTICS HOLDINGS - 19 PATIENTS IMPLANTED WITH NEURO-SPINAL SCAFFOLD;3 PATIENTS DIED WITHIN 2 WEEKS OF IMPLANTATION​ IN STUDY.INVIVO THERAPEUTICS HOLDINGS CORP - ‍16 EVALUABLE PATIENTS HAVE NOW ALL REACHED SIX-MONTH PRIMARY ENDPOINT VISIT IN STUDY​.INVIVO THERAPEUTICS - ‍DOES NOT ANTICIPATE REOPENING ENROLLMENT IN INSPIRE,EXPECTS TO PROVIDE ADDITIONAL CLARITY ON CLINICAL PATH FORWARD IN Q2 2018​.  Full Article

InVivo Therapeutics Announces Executive Management And Board Changes
Monday, 18 Dec 2017 

Dec 18 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS ANNOUNCES EXECUTIVE MANAGEMENT AND BOARD CHANGES.INVIVO THERAPEUTICS HOLDINGS CORP - ‍RICHARD TOSELLI, NAMED ACTING CHIEF EXECUTIVE OFFICER​.INVIVO THERAPEUTICS HOLDINGS CORP - ‍ TOSELLI REPLACES MARK PERRIN, WHO HAS RESIGNED AS CEO AND CHAIRMAN OF INVIVO'S BOARD OF DIRECTORS​.INVIVO THERAPEUTICS HOLDINGS CORP - ‍ TOSELLI WILL CONTINUE TO SERVE IN HIS CAPACITY AS INVIVO'S CHIEF MEDICAL OFFICER​.INVIVO THERAPEUTICS HOLDINGS CORP - ANN MERRIFIELD WAS APPOINTED AS CHAIR OF BOARD OF DIRECTORS​.  Full Article

InVivo Therapeutics reports Q3 loss per share $0.28
Monday, 30 Oct 2017 

Oct 30 (Reuters) - InVivo Therapeutics Holdings Corp :InVivo Therapeutics provides business update and reports 2017 third quarter financial results.Q3 adjusted loss per share $0.19 excluding items.Q3 loss per share $0.28.  Full Article

Invivo Therapeutics Holdings Q2 loss per share $0.16
Thursday, 4 Aug 2016 

Invivo Therapeutics Holdings Corp : Invivo Therapeutics reports 2016 second quarter financial results and business update . Q2 loss per share $0.16 . Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S .Q2 adjusted loss per share $0.18 excluding items.  Full Article

InVivo receives investigational testing authorization from Health Canada
Wednesday, 13 Jul 2016 

InVivo Therapeutics Holdings Corp :Receives investigational testing authorization from Health Canada.  Full Article

Invivo Therapeutics says Christina Morrison appointed as chairwoman of audit committee
Wednesday, 8 Jun 2016 

Invivo Therapeutics Holdings Corp - :Effective June 7, 2016, Christina Morrison was also appointed to serve as chairwoman of audit committee of board.  Full Article

Invivo Therapeutics Holdings Q1 loss per share $0.24
Friday, 6 May 2016 

Invivo Therapeutics Holdings Corp : Invivo Therapeutics reports 2016 first quarter financial results and business update .Q1 loss per share $0.24.  Full Article

Biotech CEO, two associates accused by U.S. of securities fraud

BOSTON The chief executive of a biotech company that said it was developing a non-opiate pain treatment was arrested along with two associates on Tuesday on U.S. charges that he misled investors and participated in a stock manipulation scheme.